Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	9 Months Ended		47 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
Cash flows from operating activities:
Net loss	$ (1,639)	$ (10,833)	$ (14,824)
Adjustments to reconcile net loss to Net cash used in operating activities:
Amortization	14	14	65
Depreciation	1		1
Stock based compensation relating to options	10	523	537
Shareholder contribution -3% merger fee due to MGH		687	687
Goodwill impairment		8,127	8,127
Reversal for allowance of notes receivable from SyntheMed, Inc.		(459)
Reversal of liability			(124)
Changes in operating assets and liabilities:
Increase in restricted cash		(150)
Decrease in accounts receivable	43	60	90
Decrease in interest receivable		4
Decrease in inventory	1	2	26
Decrease in prepaid expenses	116	23	160
(Decrease) increase in accounts payable	(22)	(42)	218
Increase in accrued expenses	28	420	99
Net cash used in operating activities	(1,448)	(1,624)	(4,938)
Cash flows from investing activities:
Acquisition of licenses			(90)
Payments for notes receivable		(849)	(1,173)
Cash acquired from merger		14	14
Net cash used in investing activities	0	(835)	(1,249)
Cash flows from financing activities:
Net proceeds from the issuance of common stock		1,283	1,283
Payments of insurance note payable	(98)	(8)	(160)
Proceeds from convertible notes payable	1,365	2,125	4,342
Contributions from Pathfinder, LLC members			737
Net cash provided by financing activities	1,267	3,400	6,202
Net (decrease) increase in cash	(181)	941	15
Cash at beginning of period	196	15
Cash at end of period	15	956	15
Supplementary disclosure of non-cash investing and financing activities:
Members' equity issued for license			11
Notes receivable and payable through intermediary entity			130
Long term payable for license		94	177
Financing of placement agent commission through notes payable		244	244
Financing of insurance premiums through notes payable	99	136	235
Common stock issued in settlement of Yissum liability			350
Conversion of notes into common stock		3,107	3,107
Details of merger with SyntheMed:
Fair value of assets acquired		201	201
Liabilities assumed		2,322	2,322
Non-cash consideration		$ 6,020	$ 6,020